Skip to main content
XTLB
NASDAQ Life Sciences

XTL Reports H1 2026 Loss of $899K; Discloses Psyga Deal, $1.5M Placement and New Derivative Claim

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.54
Mkt Cap
$7.486M
52W Low
$1.52
52W High
$5.64
52W Position info
1.3% above low
Off High info
73% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

XTLB is trading near its 52-week low of $1.52 (1.3% above the low).

Summary

XTL posted a $899 thousand loss for H1 2026 and disclosed the full terms of its Psyga acquisition and June private placement, alongside a new shareholder motion seeking to file a derivative claim over the 2024 Social Proxy deal.


Key Events · Earnings and Guidance · XTLB

  • H1 2026 Loss of $899 Thousand

    XTL reported a $899 thousand loss from continuing operations for the six months ended June 30, 2026, versus $1,186 thousand of income a year earlier. G&A expenses rose to $858 thousand from $510 thousand, driven by $145 thousand of share-based compensation and $151 thousand of directors' fees.

  • Psyga Acquisition Closed and Accounted For

    The company acquired 83.4% of Psyga Bio for 492,082,705 ordinary shares plus milestone warrants, with total consideration of $3,534 thousand and $3,184 thousand allocated to goodwill. The shares were issued in August 2026, after the June 30 balance sheet date.

  • $1.5 Million Placement Priced at $2.70 per ADS

    The June 29, 2026 private placement sold 555,555 ADSs at $2.70 each with Series A and B warrants and up to 555,556 contingent Series C warrants, plus a further $300 thousand round with two non-interested parties. The warrants are liability-classified and carried at $1,798 thousand at June 30, 2026.

  • Derivative Claim Motion Filed Over Social Proxy

    On August 3, 2026 a shareholder asked the Tel Aviv-Jaffa District Court for permission to bring a derivative claim against the controlling shareholder and certain current and former directors and officers over the 2024 Social Proxy acquisition, estimating damages at approximately NIS 100 million for court-fee purposes. XTL says the motion is meritless and has recorded no provision.


Analysis · XTLB · Life Sciences

XTL's first detailed look at its post-Psyga balance sheet arrives with two items that change the risk picture. The company swung to a $899 thousand loss from $1,186 thousand of income a year earlier, and its equity cushion is thin: $2,632 thousand of total equity against $3,901 thousand of liabilities. The June 29 placement raised $1,500 thousand in gross proceeds at $2.70 per ADS, well above today's $1.54 price, and the warrants attached to it sit on the balance sheet as a $1,798 thousand liability that gets remeasured each period. Separately, a shareholder filed a motion on August 3, 2026 seeking court permission to bring a derivative suit against the controlling shareholder and certain directors and officers over the 2024 Social Proxy acquisition, with damages estimated at roughly NIS 100 million for court-fee purposes. XTL calls the motion meritless and has recorded no provision. Nasdaq compliance was regained on July 20, 2026, but the company is now inside a one-year monitoring window where a fresh equity-rule breach would go straight to a delist determination with no cure period.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XTLB was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $1.52 to $5.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XTLB - Latest Insights

XTLB
Aug 05, 2026, 4:21 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $1.54 info
Change: -$1.31 (-46%) info
Market Cap: $7.486M info
XTLB
Jul 21, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $1.54 info
Change: -$1.38 (-47%) info
Market Cap: $7.486M info
XTLB
Jun 30, 2026, 5:24 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.96
Real-time Price: $1.54 info
Change: -$2.42 (-61%) info
Market Cap: $7.486M info
XTLB
Jun 30, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.85
Real-time Price: $1.54 info
Change: -$1.31 (-46%) info
Market Cap: $7.486M info
XTLB
Jun 29, 2026, 4:39 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $1.54 info
Change: -$0.820 (-35%) info
Market Cap: $7.486M info